A good jog to start the day and wake the brain up! That was the first item on the agenda of the workshop on neurodegenerative diseases, organised by Dr Britta Brix for the colleagues from the international EUROIMMUN subsidiaries. The company has by now a large number of test systems for the determination of biomarkers […]
When Dr Wolfgang Schlumberger, Vice Chairman of the Executive Board at EUROIMMUN AG visited the largest meeting for laboratory medicine in Poland, the colleagues from the EUROIMMUN subsidiary in Poland used the opportunity to ask him some questions about the in-vitro diagnostics market, about EUROIMMUN and about his beginnings in the company. “Our solutions are
In September, EUROIMMMUN will again be present at several national and international congresses and exhibitions with exciting scientific reports and own booths. You can meet us in Stuttgart on the 45th Congress of the German Society for Rheumatology from September 6th to 9th. The congress shall provide the opportunity for exchange between rheumatology and adjacent
Press release Luebeck, August 9th, 2017 EUROIMMUN is pleased to announce that European Patent EP2514837 has been revoked in its entirety in opposition proceedings by the European Patent Office in their decision dated July 7, 2017. The claims of the patent as granted relate to a method for detecting brain damage caused by Alzheimer’s disease
Since the last large Zika fever epidemic in Brazil 2015/2016, during which an association of the infectious disease with severe neurological syndromes was identified (Guillain-Barré syndrome in adults, congenital neurological damages in newborns), the demand for reliable diagnostic tests has increased extremely. With the new PCR-based direct detection, EUROIMMUN complements the existing range of serological
